Sylvain Juchet- Biostatistician at ALIMA
Sylvain Juchet
- Biostatistician at ALIMA
About
14
Publications
1,555
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
143
Citations
Introduction
Skills and Expertise
Current institution
Publications
Publications (14)
Ebola virus disease kills more than half of people infected. Since the disease is transmitted via close human contact, identifying individuals at the highest risk of developing the disease is possible on the basis of the type of contact (correlated with viral exposure). Different candidates for post-exposure prophylaxis (PEP; ie, vaccines, antivira...
Background
Data on the presentation, management, and outcomes of Lassa fever (LF) in children are limited.
Methods
Description of the clinical and biological features, treatment, and outcomes of reverse transcriptase and polymerase chain reaction (RT-PCR)-confirmed LF in children aged under 15, enrolled in the LASsa fever clinical COurse and Progn...
Background
Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%. Ribavirin is the only treatment available with worrying toxicity, questionable efficacy and low access because of its high cost. Consequently, there is an urgent need for new drugs to treat LF patients.
M...
Background:
In people with HIV (PWH), the WHO-recommended tuberculosis four-symptom screen (W4SS) targeting those who need molecular rapid test may be suboptimal. We assessed the performance of different tuberculosis screening approaches in severely immunosuppressed PWH enrolled in the guided-treatment group of the STATIS trial (NCT02057796).
Met...
Background:
As mortality remains high for patients with Ebola virus disease (EVD) despite new treatment options, the ability to level up the provided supportive care and to predict the risk of death is of major importance. This analysis of the EVISTA cohort aims to describe advanced supportive care provided to EVD patients in the Democratic Republ...
Introduction:
With the development of therapeutics and vaccine against Ebola Virus Disease, the question of post exposure prophylaxis for high risk contact emerged. Immunotherapies (monoclonal antibodies, mAbs) recently validated for treatment of infected patients appears to be good candidate to protect contacts.
Design:
During the 10th EVD outb...
Introduction
En Afrique, bien que le nombre total de décès dus a la COVID-19 semble plus faible quand dans les pays du nord, il existe peu de données sur la gravité de la maladie. Nous rapportons ici le tableau clinique et l’issue chez les malades infectés par le SARS-CoV-2 et suivis dans les centres de traitement COVID-19 (CTC) de deux pays d’Afri...
Objectives
In Africa, the overall death toll from COVID-19 is reported to be low but there is few individual-level evidence on the severity of the disease. We report the clinical spectrum and outcome of patients monitored in COVID-19 care centers (CCC) in two West-African countries.
Methods
Burkina Faso and Guinea set up referral CCCs to hospitali...
Introduction
L’Est de la République Démocratique du Congo (RDC) a été touché par une épidémie de maladie à virus Ebola (MVE) d’une ampleur sans précédent en 2019. Le taux de létalité reste élevé malgré l’accès à des traitements innovants.
Matériels et méthodes
La cohorte Ebola VIrus STAndard de soin (EVISTA) est une étude observationnelle rétrospe...
Introduction
Alors que la dixième épidémie de maladie à virus Ebola (MVE) en République Démocratique du Congo (RDC) est en cours, deux immunothérapies à base d’anticorps monoclonaux (mAbs) spécifiques du virus Ebola (EBOV), le Mab114 et le Regeneron, ont montré une efficacité sur la diminution de la létalité chez les patients atteints de MVE. La va...
Background
In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mortality after ART initiation is high in these patients, and tuberculosis and invasive bacterial diseases are common causes of death.
Methods...
Background:
In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. Cycle threshold (Ct) in the Ebola virus RT-PCR and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to EVD patients on compassionate use basis...
